Bridgeway Capital Management Inc. grew its holdings in Syndax Pharmaceuticals Inc (NASDAQ:SNDX) by 101.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 101,800 shares of the company’s stock after buying an additional 51,300 shares during the period. Bridgeway Capital Management Inc. owned 0.41% of Syndax Pharmaceuticals worth $823,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of SNDX. BlackRock Inc. raised its position in shares of Syndax Pharmaceuticals by 30.9% in the second quarter. BlackRock Inc. now owns 1,670,816 shares of the company’s stock valued at $11,729,000 after buying an additional 394,145 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Syndax Pharmaceuticals by 42.4% in the third quarter. Dimensional Fund Advisors LP now owns 795,767 shares of the company’s stock valued at $6,428,000 after buying an additional 237,042 shares during the last quarter. Stonepine Capital Management LLC acquired a new stake in shares of Syndax Pharmaceuticals in the second quarter valued at about $1,393,000. Macquarie Group Ltd. acquired a new stake in shares of Syndax Pharmaceuticals in the second quarter valued at about $1,264,000. Finally, 683 Capital Management LLC raised its position in shares of Syndax Pharmaceuticals by 32.4% in the second quarter. 683 Capital Management LLC now owns 375,000 shares of the company’s stock valued at $2,633,000 after buying an additional 91,770 shares during the last quarter. Institutional investors and hedge funds own 61.75% of the company’s stock.

A number of equities research analysts have recently commented on SNDX shares. Zacks Investment Research upgraded shares of Syndax Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.00 target price for the company in a research report on Thursday. ValuEngine cut shares of Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, November 26th. Morgan Stanley cut shares of Syndax Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $6.00 price objective for the company. in a research report on Monday, October 29th. Citigroup cut their price objective on shares of Syndax Pharmaceuticals from $15.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, October 11th. Finally, HC Wainwright cut their price objective on shares of Syndax Pharmaceuticals to $23.00 and set a “buy” rating for the company in a research report on Friday, October 26th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $17.40.

Syndax Pharmaceuticals stock opened at $4.77 on Friday. Syndax Pharmaceuticals Inc has a 12-month low of $4.36 and a 12-month high of $15.20. The stock has a market cap of $122.69 million, a P/E ratio of -1.64 and a beta of 2.65.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Monday, November 5th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.76) by $0.08. Syndax Pharmaceuticals had a negative net margin of 3,185.75% and a negative return on equity of 91.11%. The firm had revenue of $0.38 million during the quarter, compared to analysts’ expectations of $0.38 million. Analysts predict that Syndax Pharmaceuticals Inc will post -2.87 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This report was first posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/bridgeway-capital-management-inc-acquires-51300-shares-of-syndax-pharmaceuticals-inc-sndx/2669477.html.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Read More: How to Invest in an Index Fund

Want to see what other hedge funds are holding SNDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals Inc (NASDAQ:SNDX).

Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.